I
1.92
0.13 (7.26%)
AIStockmoo Score
0.5
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gradient Capital Advisors, Llc | 30 Sep 2025 | 26,808 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Nov 2025 | Announcement | MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025 |
| 21 Oct 2025 | Announcement | MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy |
| 15 Oct 2025 | Announcement | MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion |
| 09 Oct 2025 | Announcement | MindWalk Announces Share Repurchase Program |
| 22 Sep 2025 | Announcement | MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity |
| 15 Sep 2025 | Announcement | MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet |
| 10 Sep 2025 | Announcement | MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |